OnKure Therapeutics Inc(OKUR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.5 | Insider Own | 31.26% | Shs Outstand | 40.5M | Perf Week | 3.97% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | 14.87% | Insider Trans | -0.01% | Shs Float | 27.8M | Perf Month | 3.15% |
| Enterprise Value | -0.07B | PEG | - | EPS next Q | -0.41 | Inst Own | 71.73% | Short Float | 4.98% | Perf Quarter | -34.83% |
| Income | -0.06B | P/S | - | EPS this Y | 59.24% | Inst Trans | 12.94% | Short Ratio | 5.25 | Perf Half Y | -44.61% |
| Sales | 0.00B | P/B | 0.62 | EPS next 5Y | 32.97% | ROA | -44.24% | Short Interest | 1.39M | Perf YTD | -9.66% |
| Book/sh | 4.25 | P/C | 0.6 | EPS past 3/5Y | 40.79% 11.29% | ROE | -46.91% | 52W High | -51.3% ($5.38) | Perf Year | -21.79% |
| Cash/sh | 4.36 | P/FCF | - | Sales past 3/5Y | - | ROIC | -33.99% | 52W Low | 30.35% ($2.01) | Perf 3Y | -96.71% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 34.92% | Gross Margin | - | Volatility(W/M) | 8.75% 8.51% | Perf 5Y | -96.01% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 26.75 | EPS Q/Q | 72.99% | Profit Margin | - | RSI (14) | 50.88 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 26.75 | Sales Q/Q | - | SMA20 | 8.39% ($2.42) | Beta | 0.18 | Target Price | $13.67 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/4 | SMA50 | -9.84% ($2.91) | Rel Volume | 1.16 | Prev Close | $2.62 |
| Employees | 45 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 42.06% -100% | SMA200 | -27.46% ($3.61) | Avg Volume(3M) | 0.26M | Price | $2.62 |
| IPO | 2021/4/9 | Option/Short | Yes/Yes | Trades | 1865 | Volume | 306,766 | Change | - |
🧬 This is a US-based, clinical-stage biotech headquartered in Colorado that develops precision oncology drugs targeting PI3K-alpha mutations. Its pipeline features selective small-molecule inhibitors aimed at PIK3CA-mutant tumors, including breast cancer, and the company has recently undertaken a large-scale private placement to support the expansion of its pipeline.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded about as much as usual. That is 116% of its average volume.
OKUR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +59.2% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 71.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #348 of 597 in the industry
Based on market cap of $106M.
PYPD#346 Polypid Ltd $109M PER - 
ANIX#347 Anixa Biosciences Inc $108M PER - OKUR#348 OnKure Therapeutics Inc $106M PER - 
VYGR#349 Voyager Therapeutics Inc $106M PER - 
UNCY#350 Unicycive Therapeutics Inc $104M PER - 
FAQ
What kind of company is OKUR?
OKUR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OKUR?
The market cap of OKUR is approximately $106M, ranking 4,427 within its sector.
What is the 52-week high and low for OKUR?
OKUR has recorded a 52-week high of $5.38 and a low of $2.01.
